Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012:2012:382159.
doi: 10.1155/2012/382159. Epub 2012 Mar 11.

Special Agents Hunting Down Women Silent Killer: The Emerging Role of the p38α Kinase

Valentina Grossi  1 , Cristiano Simone
Affiliations

Special Agents Hunting Down Women Silent Killer: The Emerging Role of the p38α Kinase

Valentina Grossi et al. J Oncol. 2012.

Abstract

Ovarian cancer is sensitive to chemotherapy with platinum compounds; however, the therapy success rate is significantly lowered by a high incidence of recurrence and by the acquisition of drug resistance. These negative outcomes mainly depend on altered apoptotic and drug resistance pathways, determining the need for the design of new therapeutic strategies to improve patient survival. This challenge has become even more critical because it has been recognized that hindering uncontrolled cell growth is not sufficient as the only curative approach. In fact, while current therapies are mostly conceived to impair survival of highly proliferating cells, several lines of research are now focusing on cancer-specific features to specifically target malignant cells with the aim of avoiding drug resistance and reducing adverse effects. Recently, great interest has been generated by the identification of metabolic reprogramming mechanisms occurring in cancer cells, such as the increase in glycolysis levels. In this light, pharmacologic manipulation of relevant pathways involved in cancer-specific metabolism and drug resistance could prove an effective approach to treat ovarian cancer patients.

PubMed Disclaimer

Figures

Figure 1
Figure 1
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Yap TA, Carden CP, Kaye SB. Beyond chemotherapy: targeted therapies in ovarian cancer. Nature Reviews Cancer. 2009;9(3):167–181. - PubMed
    1. Berek JS. Epithelial ovarian cancer. In: Berek JS, Hacker NF, editors. Practical Gynecologic Oncology 4th edn Ch. 11 Ovarian Cancer. Philadelphia, Pa, USA: Lippincott Williams & Wilkins; 2005. pp. 443–511.
    1. Watson P, Lynch HT. Extracolonic cancer in hereditary nonpolyposis colorectal cancer. Cancer. 1993;71(3):677–685. - PubMed
    1. Rubin SC, Blackwood MA, Bandera C, et al. BRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: relationship to family history and implications for genetic testing. American Journal of Obstetrics and Gynecology. 1998;178(4):670–677. - PubMed
    1. Singer G, Oldt R, III, Cohen Y, et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. Journal of the National Cancer Institute. 2003;95(6):484–486. - PubMed

LinkOut - more resources